Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
EAA172
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
- NCT03701321 ↗
- Withdrawn
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on EAA172 (venetoclax, bortezomib and 2 more in Recurrent Plasma Cell Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EAA172 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
- Phase
- Phase 1/Phase 2
- Status
- Withdrawn
- Conditions
- Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
- Interventions
- Bortezomib; Daratumumab; Dexamethasone; Venetoclax
- Arms
- Phase I (DVd, venetoclax) · Experimental
- Phase II Arm D (DVd, venetoclax) · Experimental
- Phase II Arm E (DVd) · Active comparator
- Enrollment
- 0
- Primary outcomes
- Maximum tolerated dose of venetoclax in combination with daratumumab, bortezomib and dexamethasone (Phase I)
- Minimal residual disease (MRD) negative status (Phase II)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jan 25, 2019 (estimated)
- Primary completion
- May 28, 2020 (estimated)
- Results posted
- No
- Registry record
- NCT03701321 · updated Sep 26, 2023